Filing Flows › Bionano Genomics (BNGO) › Q2 2026
Bionano Genomics (BNGO) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
Bionano Genomics (BNGO) reported revenue of $8.2M for the second quarter 2026 (Q2 2026), +21% from a year earlier and +22% from the quarter before. Operating margin was -88.3%, net loss $7.4M (90.8% of revenue).
Bionano Genomics, Q2 2026: revenue $8.2M (+21% year over year), operating margin -88.3%, net loss $7.4M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $8.2M | +22% | +21% |
| Operating profit | −$7.2M | — | — |
| Net earnings | −$7.4M | — | — |
| Operating cash flow | −$4.7M | — | — |
What changed
Revenue was $8.2M in Q2 2026, up 21% year over year and up 22% from the previous quarter. Consumable Revenue was the largest line at 52% of revenue. Consumable Revenue added $1.0M year over year (up 31%), 70% of the total change. Software Revenue declined 16%.
Operating costs exceeded revenue by $7.2M, an operating margin of -88.3%. Total costs grew 6% against revenue growth of 21%. The fastest-growing cost line was Cost of revenue (+18%). The quarter ended with a net loss of $7.4M, narrower than the previous quarter's $8.3M loss.
Operating cash flow was −$4.7M. Non-cash charges added back $2.3M of depreciation and amortization and $1.0M of share-based compensation. Working capital and other items used $513K.
Questions
What was Bionano Genomics' revenue in the second quarter 2026?
Bionano Genomics (BNGO) reported revenue of $8.2M for the second quarter 2026 (Q2 2026), +21% from a year earlier and +22% from the quarter before.
Was Bionano Genomics profitable in the second quarter 2026?
Operating loss was $7.2M (-88.3% of revenue) and net loss $7.4M.
Source: Bionano Genomics 10-Q on SEC EDGAR.